<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832507</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-235-0101</org_study_id>
    <nct_id>NCT00832507</nct_id>
  </id_info>
  <brief_title>Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study
      will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to
      placebo in subjects with PAH. Study drug will be administered alone, or on the background of
      stable PAH therapy. The study will consist of 3 periods: a screening period, a 12-week
      placebo-controlled treatment period, and a long-term, blinded extension period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare the change in exercise capacity following
      treatment with cicletanine HCl or placebo in subjects with PAH.

      The secondary objectives of this study are:

        1. To compare the change in other clinical measures of PAH following treatment with
           cicletanine HCl or placebo in subjects with PAH

        2. To compare the safety and tolerability of cicletanine HCl to placebo in subjects with
           PAH Additionally, the long-term safety, tolerability, and efficacy of cicletanine HCl
           treatment will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in six-minute walk distance (6MWD) evaluated after 12 weeks of treatment</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BDI, WHO Functional Class, BNP, cardiac hemodynamics and SF-36 physical functioning scale following 12 weeks of treatment. In addition, time to clinical worsening (TTCW) will be evaluated.</measure>
    <time_frame>Baseline to Week 60</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Cicletanine 150 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cicletanine 150 mg administered once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cicletanine 150 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cicletanine 150 mg administered twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cicletanine 300 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cicletanine 300 mg administered once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match cicletanine administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cicletanine</intervention_name>
    <description>Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily</description>
    <arm_group_label>Cicletanine 150 mg QD</arm_group_label>
    <arm_group_label>Cicletanine 150 mg BID</arm_group_label>
    <arm_group_label>Cicletanine 300 mg QD</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cicletanine Placebo</intervention_name>
    <description>Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Between 16 and 70 years of age

          -  Weigh greater than or equal to 40 kg

          -  Have a current diagnosis of IPAH, FPAH, or PAH that is primarily due to: connective
             tissue disease, congenital heart defects, drug and toxin use, and HIV infection

          -  Meet all of the following hemodynamic criteria by means of a RHC completed prior to or
             during Screening: mPAP of greater than or equal to 25 mmHg, PVR greater than 240
             dyne.sec/cm5, PCWP or LVEDP of less than or equal to1 5 mmHg

          -  Walk a distance of at least 100 m but no more than 450 m during the screening 6MWT

          -  Have WHO functional class II, III, or IV symptoms

          -  Meet all of the following pulmonary function tests completed no more than 12 weeks
             before the Screening visit: TLC greater than or equal to 60% of predicted normal &amp;
             FEV1 greater than or equal to 65% of predicted normal, FEV1:FVC ratio greater than
             0.60

          -  Have laboratory results within 90% of the lower limit of normal to 1.5 times the upper
             limit of normal

          -  Receiving treatment with an approved ERA, PDE5i, and/or parenteral prostanoid must be
             receiving this therapy for greater than or equal to 12 weeks prior to the Screening
             Visit and must be at a stable dose for greater than or equal to 4 consecutive weeks
             prior to the Screening Visit.

          -  Eligible therapies allowed at Screening include:a. Monotherapy with an ERA, PDE5i, or
             parenteral prostanoid that is approved for the treatment of PAH b. Combination therapy
             with two eligible PAH treatments (any combination of ERA, PDE5i, or parenteral
             prostanoid

          -  Subject receiving diuretic treatment must be on stable therapy

          -  If receiving digitalis, CCBs, angiotensin receptor blockers (ARBs), angiotensin
             converting enzyme (ACE) inhibitors, or beta-blocking agents subject must be on stable
             therapy

          -  If receiving HMG-CoA reductase inhibitors, subject must be on stable therapy

          -  If diagnosis of HIV subject must have stable disease status

          -  Female subjects of childbearing potential must have a negative serum pregnancy test

          -  Female subjects of childbearing potential must agree to use 2 reliable methods of
             contraception

          -  Must agree not to participate in a clinical study involving another investigational
             drug or device

          -  Must be competent to understand and sign the IRB approved ICF

          -  Has not enrolled in an exercise training program for pulmonary rehabilitation and must
             agree not to enroll in an exercise training program for pulmonary rehabilitation

          -  If subject has been enrolled in an exercise training program for pulmonary
             rehabilitation for greater than 12 weeks prior to the Screening Visit and must agree
             to maintain their current level of rehabilitation for the first 12 weeks of the study

          -  Must be on background PAH therapy at Screening unless the subject does not have access
             to or can not tolerate currently approved PAH medical therapies

        Exclusion Criteria

          -  Subject with a current PH diagnosis other than IPAH, FPAH, or PAH that is primarily
             due to: Connective tissue disease, Congenital heart defects, Drug and toxin use, or
             HIV infection

          -  Subject with LVEF less than or equal to 40% or clinically significant ischemic,
             valvular, or constrictive heart disease

          -  Subject with WHO functional class I symptoms

          -  Subject has chronically received an ineligible PAH treatment regimen within the 4
             weeks prior to the Screening Visit, specifically: a. inhaled iloprost or inhaled
             treprostinil, b. combination treatment with three PAH therapies, c.any investigational
             therapy for the treatment of PAH d.Chronic use is considered greater than 7
             consecutive days of treatment

          -  Subject receiving iv inotropes within 2 weeks prior to the Screening Visit

          -  Subject with SBP greater than or equal to 150 mmHg or less than 90mmHg

          -  Subject with moderate to severe liver disease

          -  Subject with moderate or severe renal impairment

          -  Subject receiving lithium within the 2 weeks prior to the Screening Visit

          -  Subject requiring intermittent or chronic treatment with nitrates

          -  Subject receiving non-anti-arrhythmic drugs

          -  Subject has a diagnosis of long QT syndrome

          -  Subject with evidence of chronic thromboembolic disease

          -  Subject with obstructive lung disease

          -  Subject with severe arthritis, musculoskeletal problems, or morbid obesity that would
             affect the subject's ability to perform or complete the 6MWT

          -  Has a history of malignancies within the past 5 years

          -  Subject with disease that may adversely affect the safety of the subject and/or
             efficacy of the study drug or severely limit the lifespan of the subject

          -  Female subject who is pregnant or breastfeeding

          -  Has demonstrated noncompliance with previous medical regimens

          -  Has a recent history of abusing alcohol or illicit drugs

          -  Has participated in a clinical study involving another investigational drug or device
             within 4 weeks before the Screening Visit

          -  Has a known hypersensitivity to the study drug, the metabolites, or formulation
             excipients

          -  Receiving an oral arginine supplement within 2 weeks prior to the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gennyne Walker, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Senior Clinical Research Scientist, Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Greater LA Healthcare System</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harish H. K. Murthy, MD</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Heart and Lung Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1252</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Klinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Klinik Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Lougheed Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universitaet</name>
      <address>
        <city>Muenchen</city>
        <state>BY</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg</name>
      <address>
        <city>Giessen</city>
        <state>HE</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación Clínica en Medicina S.C.</name>
      <address>
        <city>Monterrey</city>
        <state>NL</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiologia Ignacio Chavez</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Gt Lon</state>
        <zip>NW32QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2009</study_first_posted>
  <disposition_first_submitted>January 3, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 3, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 4, 2014</disposition_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>cicletanine</keyword>
  <keyword>cicletanine HCL</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>endothelin receptor antagonist</keyword>
  <keyword>ERA</keyword>
  <keyword>monotherapy</keyword>
  <keyword>combination therapy</keyword>
  <keyword>phosphodiesterase type-5 inhibitor</keyword>
  <keyword>PDE5i</keyword>
  <keyword>parenteral prostanoid</keyword>
  <keyword>PH</keyword>
  <keyword>pulmonary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
    <mesh_term>Cicletanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

